The Latest Breaking News from Novo Nordisk

Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor

Suzette Zuena is her own best advertisement for weight loss.

Ozempic and Wegovy started as injectable diabetes treatments. But now, these “appetite suppressants” are being touted as miracle weight loss drugs.

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

A panel of advisers to the WHO will review requests for drugs to be included next month

Fast-acting insulin Fiasp has been a "game changer" for Daniel Webb in managing his type 1 diabetes. The drug was about to be removed from the PBS, but a temporary solution has been found.

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

LOS ANGELES — California Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.

Pharmaceutical company behind blockbuster diet jab Wegovy confronts crises on multiple fronts, amid scrutiny of UK activities